Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7297
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    82.81
    0.00 (0.00%)
     

  • Bitcoin CAD

    87,727.70
    -3,201.41 (-3.52%)
     

  • CMC Crypto 200

    1,384.06
    -40.04 (-2.81%)
     

  • GOLD FUTURES

    2,329.10
    -9.30 (-0.40%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,472.00
    -192.50 (-1.09%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

GW Pharmaceuticals PLC (GWPH) Outpaces Stock Market Gains: What You Should Know

Zacks Equity Research

GW Pharmaceuticals PLC (GWPH) closed at $129.65 in the latest trading session, marking a +1.73% move from the prior day. This change outpaced the S&P 500's 0.19% gain on the day. Meanwhile, the Dow lost 0.11%, and the Nasdaq, a tech-heavy index, added 0.81%.

Heading into today, shares of the company had gained 4.54% over the past month, outpacing the Medical sector's loss of 1.57% and the S&P 500's gain of 0.56% in that time.

GWPH will be looking to display strength as it nears its next earnings release, which is expected to be November 5, 2019. On that day, GWPH is projected to report earnings of -$0.85 per share, which would represent year-over-year growth of 69.2%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $88.26 million, up 3547.11% from the year-ago period.

Investors might also notice recent changes to analyst estimates for GWPH. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

ADVERTISEMENT

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1% lower. GWPH is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 38% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow GWPH in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research